TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has appointed Anna Moore, PhD, as Chair of its Scientific Advisory Board and entered into a sponsored research agreement with Michigan State University, the company announced today. These developments aim to accelerate the company's RNA-based therapeutic pipeline, particularly its lead candidate TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.
The research agreement with Michigan State University is expected to support further development of TTX-MC138, including evaluation in combination with other therapies. Dr. Moore, a renowned expert in molecular imaging and nanomedicine, will provide strategic guidance on research and development efforts focused on treating advanced cancers. Her appointment brings significant expertise to TransCode's scientific advisory board, which will oversee the company's preclinical and clinical programs.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA-based treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is designed to treat metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates intended to mobilize the immune system to recognize and destroy cancer cells.
The full press release is available at https://ibn.fm/NA2NH. For the latest news and updates on TransCode Therapeutics, visit the company's newsroom at https://ibn.fm/RNAZ.
These strategic moves underscore TransCode's commitment to advancing its RNA-based therapeutic platform, which holds promise for addressing unmet medical needs in oncology. The collaboration with Michigan State University and the leadership of Dr. Moore are expected to enhance the company's research capabilities and accelerate the development of novel cancer treatments.
